MedTrace Logo

SANGUINATE™ in Sickle Cell Disease Associated Leg Ulcer

NCT02600390 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2017-02-28

No results posted yet for this study

Summary

SANGUINATE™ Sickle Cell Disease associated Leg Ulcers.

Conditions

  • Leg Ulcer

Interventions

BIOLOGICAL

SANGUINATE

A two-hour infusion provided once a week over a 4-week or 6-week period.

Sponsors & Collaborators

  • Prolong Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Hemant Misra, PhD · Prolong Pharma

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2016-10-31
Completion
2016-11-30

Countries

  • Dominican Republic
  • Panama

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02600390 on ClinicalTrials.gov